Добірка наукової літератури з теми "Cellules souches autologues"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Cellules souches autologues".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Cellules souches autologues":
Yazbeck, C. "Cellules souches autologues en thérapie endométriale : espoir ou illusion ?" Gynécologie Obstétrique & Fertilité 44, no. 11 (November 2016): 616–17. http://dx.doi.org/10.1016/j.gyobfe.2016.09.006.
Birebent, Brigitte, and Anne Legendre. "Stabilité des greffons de cellules souches hématopoïétiques (CSH) autologues décongelés." Transfusion Clinique et Biologique 24, no. 3 (September 2017): 375. http://dx.doi.org/10.1016/j.tracli.2017.06.293.
Magalon, G., R. Legré, M. Chammas, J. P. Marie, P. Decherchi, F. Sabatier, J. Veran, et al. "Réparer les nerfs périphériques lésés avec des greffes autologues de cellules souches olfactives nasales." Hand Surgery and Rehabilitation 37, no. 6 (December 2018): 413–14. http://dx.doi.org/10.1016/j.hansur.2018.10.096.
Dubois-Laforgue, Danièle. "Transplantation de cellules souches autologues dans le diabète de type 1 récent : des résultats mitigés." Médecine des Maladies Métaboliques 9, no. 4 (June 2015): 66–67. http://dx.doi.org/10.1016/s1957-2557(15)30186-3.
Astrugue, C., S. Dieterlé, and S. Lucas-Samuel. "Proportion de faibles rendements en CD34+ des greffons de cellules souches hématopoïétiques autologues après décongélation en France." Revue d'Épidémiologie et de Santé Publique 71 (March 2023): 101498. http://dx.doi.org/10.1016/j.respe.2023.101498.
Raposio, E., S. Bonomini, and F. Calderazzi. "Isolement des cellules souches mésenchymateuses autologues dérivées du tissu adipeux pour la réparation des pertes de substance osseuse." Revue de Chirurgie Orthopédique et Traumatologique 102, no. 7 (November 2016): 656. http://dx.doi.org/10.1016/j.rcot.2016.07.022.
Soler, Pauline, Mathilde Rousselet, Julia Nadolny, Florence Castaldo, and Sandrine Fleury. "L21-4 Analyse de l’impact du choix du séparateur sur les résultats des recueils de cellules souches autologues." Transfusion Clinique et Biologique 30 (November 2023): S21—S22. http://dx.doi.org/10.1016/j.tracli.2023.09.354.
Stanovici, Julien, Philippe Rosset, Louis-Romée Le Nail, Jérôme Druon, Sandrine Fleury, Luc Sensebe, and Pierre Layrolle. "Résultats de 7 pseudarthroses des os longs chez l’homme traitées par cellules-souches mésenchymateuses autologues cultivées associées à des biomatériaux." Revue de Chirurgie Orthopédique et Traumatologique 101, no. 7 (November 2015): S221—S222. http://dx.doi.org/10.1016/j.rcot.2015.09.201.
BICH, C. S., V. GUÉRIF, V. DEWOLF, A. DUHOUX, M. BRACHET, P. DUHAMEL, and É. BEY. "Brûlures radiologiques." Revue Médecine et Armées, Volume 50, Numéro 2 (June 6, 2024): 75–86. http://dx.doi.org/10.17184/eac.8640.
Boissier, R., S. Garcia, S. Giusiano, F. Sabatier, F. Dignat-Georges, S. Berdah, G. Magalon, and G. Karsenty. "Évaluation des effets de l’injection endoscopique de cellules souches mésenchymateuses autologues issues du tissu adipeux dans un modèle porcin d’insuffisance sphinctérienne." Progrès en Urologie 22, no. 13 (November 2012): 781–82. http://dx.doi.org/10.1016/j.purol.2012.08.097.
Дисертації з теми "Cellules souches autologues":
Li, Yan. "Thérapie cellulaire cardiaque avec cellules souches mésenchymateuses médullaires autologues : étude expérimentale de la bio-disponibilité et la bio-distribution du greffon cellulaire." Nancy 1, 2006. http://www.theses.fr/2006NAN11318.
Myocardial infarction (MI) results in an apparent loss of contractile cardiomyocytes, a diminution of cardiac vessels (angiogenesis) which are responsible for the progressive alteration in the cardiac architecture and function. Recently, the reconstruction of the damaged cardiac tissue by using autologous stem cells (cardiac cell therapy) based partly on their ability to give rise to new cardiomyocytes and/or to promote angiogenesis has been proposed as a new therapeutic approach of the cardiac cell therapy. This thesis describes difIerent steps of pre-clinical investigation in order to assess the capability of bone marrow, derived mesenchymal stem cells (BMSCs) to repair infarct and necrotic myocardium. After initial phases of validation of various techniques of BMSCs' selection (cell harvesting, culture and phenotype characterization) and the development of a rat model of myocardial infarction by permanent coronary ligation, the main focus of this project was to develop new investigational methodologies allowing to track non-invasively implanted therapeutic cells. Therefore, the number of engrafted cells, their relative distribution within infarct versus normal myocardial tissue might be precisely determined and sequentially followed up. Outcomes from the bio-availability and the bio-distribution of grafted cells might have a critical importance when analyzing the effects of cardiac cell therapy and contribute to improve the cell therapeutic indication
Lerouxel, Emmanuelle Giumelli Bernard Malard Olivier. "Phosphates de calcium et cellules autologues base d'une ingénierie tissulaire pour la reconstruction osseuse en territoire irradié /." [S.l.] : [s.n.], 2007. http://castore.univ-nantes.fr/castore/GetOAIRef?idDoc=57226.
Lerouxel, Emmanuelle. "Phosphates de calcium et cellules autologues : base d'une ingénierie tissulaire pour la reconstruction osseuse en territoire irradié." Nantes, 2007. https://archive.bu.univ-nantes.fr/pollux/show/show?id=bc057180-d0dc-4d31-8f81-a716260ff382.
Treatment of most forms of squamous cell carcinoma requires surgical procedures and high dose irradiation, which often produce major esthetic and functional injuries in the maxillofacial area. Radiotherapy produces irreversible side-effects on bone, involving damages to its reparation properties and complications such as infections, healing delays and osteoradionecrosis (ORN). Synthetic biphasic Calcium Phosphates (CaP) have been used extensively as bone substitutes in maxillofacial and dental applications as alternatives to autologous bone without irradiation. The aim of this rat study was to determine the influence on osseous repair of autologous cells grafts, bone marrow (BM) or mesenchymal stem cells (MSC), added to CaP ceramics, used as granules or injectable form, in previously irradiated bone. The development of an animal model of localized ORN has been previously developed. Ceramics were biotolerated, yet with low osteoconductive properties in irradiated bone. The BM grafts led to a significant increase in bone in growth in the irradiated areas. BM or adipose tissue derived MSC were not able to enhance bone ingrowth in irradiated osseous defects. These results could be explained by BM resources in cells and in growth factors indispensable for osseous repair. These results allow to highlight the interest of bone substitution by association of CaP ceramics and BM grafts in irradiated bone. Further studies will have to assess the role of grafted cells in osteogenesis and neoangiogenesis. This study allows also to foresee ORN treatment with tissue engineered materials
Perez, Castiglioni Monica Patricia. "Le statut juridique des cellules souches : de la greffe d’organes à la thérapie cellulaire." Electronic Thesis or Diss., Paris 8, 2021. http://www.theses.fr/2021PA080048.
Stem cells as cellular products for therapeutic purposes (PCT) or as advanced therapy drugs (ITNs) within the framework of regenerative medicine have revolutionized the medicine of the 21st century. Faced with recent discoveries of new stem cells created by researchers (parthenotes, cloned stem cells, iPS cells), other possibilities for regenerative therapy are emerging over time.The law, which has always accompanied the scientific and technical development of cell therapy since the 17th century, must be more present than ever to protect human beings who lend themselves to new treatments or to experimentation. The historical development of this therapeutic revolution allows us to show the importance of legal and ethical reflection for scientific progress.Old questions, such as the status of the prenatal being and the authorization for cryopreservation of autologous tissues or cells, are re-emerging in the face of the presence of supernumerary human embryonic stem cells and the success of regenerative therapy. Teratogenic treatments and episodes of child abuse during pregnancy have destroyed or damaged thousands of unborn children. Recognition of prenatal life is offered in certain circumstances to protect the embryo and fetus before birth
Sadelli, Kevin. "Potentiel thérapeutique des transplantations autologues et syngéniques de cellules souches olfactives ecto-mésenchymateuses (CSO-EMS) dans deux modèles d'atteintes du système nerveux central (SNC)." Thesis, Aix-Marseille, 2017. http://www.theses.fr/2017AIXM0669.
The main goal of my thesis was to evaluate whether autografts of ecto-mesenchymal olfactory stem cell (EM-OSCs) restored learning and memory abilities in a rats model of amnesia following global cerebral ischemia (GCI). The latter can occur following cardiac arrest (CA) and lead to deleterious neurological consequences such as cognitive and / or sensorimotor injuries.Finally, the final step in my project was to evaluate the effect of EM-OSCs autografts on restoration of cognitive functions in ischemic rats. First of all, I had to develop a protocol to monitor the fate of EM-OSCs following autografts, without altering their endogenous properties. Then, I demonstrated that these GFP+ EM-OSCs autografts: i) restored learning and memory abilities, ii) stimulated neurogenesis, and iii) improved PLT in ischemic rats. All the data gathered during my thesis give credibility to the use of EM-OSCs in the framework of therapies against the CNS damages
Rakic, Rodolphe. "Nouvelles stratégies thérapeutiques des affections articulaires du cheval : évaluation du potentiel thérapeutique des chondrocytes autologues et des cellules souches de cordon ombilical (sang et gelée de Wharton) : vers l'industrialisation de cellules médicaments." Thesis, Normandie, 2017. http://www.theses.fr/2017NORMC406/document.
Articular cartilage disorders, such as focal defects and osteoarthritis, are the main causes of decreased performance or early retirement of sport- and racehorses. Thus, cartilage disorders represent a major veterinary issue in the equine industry, due to significant financial losses. Poor intrinsic cartilage repair properties and the absence of long- term therapy for cartilage defects lead to the development and use of new generation therapies such as autologous chondrocytes implantation. In this context, our study aimed to compare different cell types for the in vitro cartilage generation, in order to implant the biological substitute to treat cartilage defects in the horse. A therapeutic strategy initially developed in human medicine, the autologous chondrocytes transplantation, always represents a "gold standard" in cartilage tissue engineering. In the present study, after developing a new generation of cartilaginous substitute of high biological quality, composed of equine articular chondrocytes, technical and biological limits inherent to the cell type persist. Thus, we have used alternative cell types such as neonatal mesenchymal stem/stromal cells (MSCs) from umbilical cord, such as umbilical cord blood MSC (UCB-MSCs) and umbilical cord matrix or Wharton jelly MSCs (UCM- MSCs). These MSCs sources could represent a therapeutic advantage due to their non-invasive isolation, their high cell proliferation and their ability to differentiate into chondrocytes. Nevertheless, it is essential to define the best therapeutic candidate between these two MSCs sources, to obtain an optimal quality for the neocartilaginous substitute. Our data highlighted important differences in the chondrogenesis process of these two neonatal MSCs sources, allowing us to consider UCB-MSCs as the best therapeutic candidate for equine cartilage tissue engineering. This work allows a better understanding of the chondrocyte and MSCs biology. Moreover, this work leads the way to setting-up future clinical trials in the horse, in order to treat articular defects of this large animal model
Lorme, Bertrand de. "Etude de la qualité du greffon et de la récupération hématologique après chimio-intensification avec support de cellules souches périphériques autologues dans les tumeurs solides et les lymphopathies." Montpellier 1, 1998. http://www.theses.fr/1998MON11154.
Marsol, Marie-Christine. "Traitement de la maladie de Kahler par autogreffe de cellules souches périphériques chez 14 patients." Bordeaux 2, 1990. http://www.theses.fr/1990BOR25082.
Rice, Alison Mary. "Caractérisation fonctionnelle des cellules souches sanguines mobilisées par chimiothérapie." Bordeaux 2, 1993. http://www.theses.fr/1993BOR28240.
GRAVIS, GWENAELLE. "Chimiotherapie a haute dose avec reinjection de cellules souches hematopoietiques dans les adenocarcinomes mammaires." Aix-Marseille 2, 1994. http://www.theses.fr/1994AIX20855.
Тези доповідей конференцій з теми "Cellules souches autologues":
Ferre, F. "Des greffes autologues aux cellules souches, quel avenir pour la chirurgie pré-implantaire ?" In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206601005.